Search - tctmd.com

Displaying 141 - 160 of 244

Sort: Relevancy | Date

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Shelley Wood

August 05, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

Shelley Wood

July 31, 2019

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Shelley Wood

July 23, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Conference News SCAI 2019

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Yael L. Maxwell

May 30, 2019

News Conference News ESC Heart Failure 2019

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

Shelley Wood

May 28, 2019

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

News Conference News ACC 2019

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

Shelley Wood

March 19, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

Majority of SCAD Lesions Heal With Conservative Treatment

Michael O'Riordan

February 27, 2019

News Daily News

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

L.A. McKeown

January 31, 2019

News Daily News

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

Michael O'Riordan

January 11, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

News Daily News

Many PCI Patients Treated in China Have No Angina Symptoms

Caitlin E. Cox

December 20, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

Advertisement

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

TCTMD’s Top 10 Most Popular Stories for July 2019

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Majority of SCAD Lesions Heal With Conservative Treatment

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Top News in Coronary Artery Disease: 2018

Many PCI Patients Treated in China Have No Angina Symptoms

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content